nach oben

Supportive Care in Cancer

Erschienen in:

28.07.2018 | Review Article

Subcutaneous or intravenous opioid administration by patient-controlled analgesia in cancer pain: a systematic literature review

verfasst von: Lisa Nijland, Pia Schmidt, Michael Frosch, Julia Wager, Bettina Hübner-Möhler, Ross Drake, Boris Zernikow

Erschienen in: Supportive Care in Cancer | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Context

Opioids administered by various routes are a mainstay of tumour-related pain management. Subcutaneous or intravenous patient-controlled analgesia (PCA) with opioids is an appropriate and safe form of treatment for postoperative pain but studies on this form of administration are sparse in the setting of cancer pain despite widespread use.

Objective

To evaluate the published studies on opioids administered by subcutaneous and intravenous patient-controlled analgesia for patients with cancer pain.

Methods

Articles were identified from the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 7, 2016), PubMed (Medline; 1975 to 2016) and EMBASE (1974 to 2016). Additional reports were identified from the reference lists of retrieved papers. Studies based on original data with a focus on intravenous or subcutaneous PCA administration of opioids in patients suffering from cancer-related pain were selected. The language was restricted to Dutch, English or German. Predefined information was extracted depending on the topic.

Results

Fifty studies published since 1980 met the inclusion criteria. A wide range of study designs, study quality and research objectives were observed. The studies indicated use of standard or by proxy PCA in the inpatient and outpatient setting were safe and useful while significant adverse effects were rarely observed.

Conclusion

This systematic review of the current evidence suggests PCA can be appropriately used in a wide range of clinical situations.

Nur mit Berechtigung zugänglich

McGrath PJ, Walco GA, Turk DC, Dworkin RH, Brown MT, Davidson K, Eccleston C, Finley AG, Goldschneider K, Haverkos L, Hertz S, Ljungman G, Palermo T, Rappaport BA, Rhodes T, Schechter N, Scott J, Sethna NF, Svensson OK, Stinson J, von Baeyer CL, Walker L, Weisman S, White RE, Zajicek A, Zeltzer L (2008) Core outcome domains and measures for pediatric acute and chronic/recurrent pain clinical trials: PedIMMPACT recommendations. J Pain 9(9):771–783PubMedCrossRef

O’Connor AB, Turk DC, Dworkin RH, Katz NP, Colucci R, Haythornthwaite JA, Klein M, O’Brien C, Posner K, Rappaport BA, Reisfield G, Adams EH, Balster RL, Bigelow GE, Burke LB, Comer SD, Cone E, Cowan P, Denisco RA, Farrar JT, Foltin RW, Haddox JD, Hertz S, Jay GW, Junor R, Kopecky EA, Leiderman DB, McDermott MP, Palmer PP, Raja SN, Rauschkolb C, Rowbotham MC, Sampaio C, Setnik B, Smith SM, Sokolowska M, Stauffer JW, Walsh SL, Zacny JP (2013) Abuse liability measures for use in analgesic clinical trials in patients with pain: IMMPACT recommendations. Pain 154(11):2324–2334. https://doi.org/10.1016/j.pain.2013.06.035 PubMedCrossRef

Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, Cleeland C, Dionne R, Farrer JT, Galer BS, Hewitt DJ, Jadad AR, Katz NP, Kramer LD, Manning DC, McCormick CG, McDermott MP, McGrath PA, Quessy S, Rappaport BA, Robinson JP, Royal MA, Lee S, Stauffer JW, Stein W, Tollett J, Witter J (2003) Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain 106(337):345

Schiessl C, Bidmon J, Sittl R, Griessinger N, Schüttler J (2007) Patient-controlled analgesia (PCA) in outpatients with cancer pain—analysis of 1,692 treatment days. Schmerz 21(1):35–42PubMedCrossRef

Reale C, Vernaglione E, Reale CA, Mancini A, Prologo M, Campisi C (2003) Advantages of totally implanted port over impromptu short-term central venous catheter in oncological pain therapy. J Vasc Access 4(2):50–55PubMedCrossRef

Sousa AM, de Santana NJ, Guimaraes GM, Cascudo GM, Neto JOB, Ashmawi HA (2014) Safety profile of intravenous patient-controlled analgesia for breakthrough pain in cancer patients: a case series study. Support Care Cancer 22(3):795–801PubMedCrossRef

Hayes J, Dowling JJ, Peliowski A, Crawford MW, Johnston B (2016) Patient-controlled analgesia plus background opioid infusion for postoperative pain in children: a systematic review and meta-analysis of randomized trials. Anesth Analg 123(4):991–1003PubMedCrossRef

McNicol ED, Ferguson MC, Hudcova J (2015) Patient controlled opioid analgesia versus non-patient controlled opioid analgesia for postoperative pain. Cochrane Database Syst Rev 2015 6 (Art. No.: CD003348.). doi:https://doi.org/10.1002/14651858.CD003348.pub3

Schiessl C, Schestag I, Sittl R, Drake R, Zernikow B (2010) Rhythmic pattern of PCA opioid demand in adults with cancer pain. Eur J Pain 14(4):372–379PubMedCrossRef

10.

Whittemore R, Knafl K (2005) The integrative review: updated methodology. J Adv Nurs 52(5):546–553PubMedCrossRef

11.

Ruggiero A, Barone G, Liotti L, Chiaretti A, Lazzareschi I, Riccardi R (2007) Safety and efficacy of fentanyl administered by patient controlled analgesia in children with cancer pain. Support Care Cancer 15(5):569–573PubMedCrossRef

12.

Bruera E, Brenneis C, Michaud M, Bacovsky R, Chadwick S, Emeno A, MacDonald N (1988) Use of the subcutaneous route for the administration of narcotics in patients with cancer pain. Cancer 62(2):407–411PubMedCrossRef

13.

Bruera E, MacMillan K, Hanson J, MacDonald RN (1991) The Edmonton injector: a simple device for patient-controlled subcutaneous analgesia. Pain 44(2):167–169PubMedCrossRef

14.

Anghelescu DL, Snaman JM, Trujillo L, Sykes AD, Yuan Y, Baker JN (2015) Patient-controlled analgesia at the end of life at a pediatric oncology institution. Pediatr Blood Cancer 62(7):1237–1244. https://doi.org/10.1002/pbc.25493 PubMedPubMedCentralCrossRef

15.

Baumann TJ, Batenhorst RL, Graves DA (1986) Patient-controlled analgesia in the terminally ill cancer patient. Drug Intell Clin Pharm 20:297–301PubMedCrossRef

16.

Bruera E, Michaud M, Brennels C, MacMillan K, MacDonald N (1988) A randomized cross-over trial of patient controlled subcutaneous analgesia versus continuous subcutaneous in patients with cancer pain. Proceedings, annual meeting of the American Society of Clinical Oncology Abs. 1107

17.

Bruera E, Velasco-Leiva A, Spachynski K, Fainsinger R, Miller MJ, MacEachern T (1993) Use of the Edmonton injector for parenteral opioid management of cancer pain: a study of 100 consecutive patients. J Pain Symptom Manag 8(8):525–528CrossRef

18.

Citron ML, Johnston-Early A, Boyer M (1986) Patient-controlled analgesia for severe cancer pain. Arch Intern Med 146(4):734–736PubMedCrossRef

19.

Citron ML, Kalra JM, Seltzer VL, Chen S, Hoffman M, Walczak MB (1992) Patient-controlled analgesia for cancer pain: a long-term study of inpatient and outpatient use. Cancer Investig 10(5):335–341CrossRef

20.

Dev R, Del Fabbro E, Bruera E (2011) Patient-controlled analgesia in patients with advanced Cancer. Should patients be in control? J Pain Symptom Manage i

21.

Enting RH, Oldenmenger WH, van der Rijt CCD, Wilms EB, Elfrink EJ, Elswijk I, Sillevis Smitt PAE (2002) A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral opioids. Cancer 94(11):3049–1056PubMedCrossRef

22.

Flory JH, Wiesenthal AC, Thaler HT, Koranteng L, Moryl N (2016) Methadone use and the risk of hypoglycemia for inpatients with cancer pain. J Pain Symptom Manag 51(1):79–87. e71CrossRef

23.

Kalso E, Heiskanen T, Rantio M, Rosenberg PH, Vainio A (1996) Epidural and subcutaneous morphine in the management of cancer pain: a double-blind cross-over study. Pain 67(2):443–449PubMedCrossRef

24.

Miser AW, Miser JS, Clark C (1980) Continuous intravenous infusion of morphine sulfate for control of severe pain in children with terminal malignancy. J Pediatr 96:930–932PubMedCrossRef

25.

Sabatowski R, Kasper SM, Radbruch L (2002) Patient-controlled analgesia with intravenous L-methadone in a child with cancer pain refractory to high-dose morphine. J Pain Symptom Manag 23(1):3–5CrossRef

26.

Tobias JD, Baker DK (1992) Patient-controlled analgesia with fentanyl in children. Clin Pediatr 31(3):177–179CrossRef

27.

Vanier MC, Labrecque G, Lepage-Savary D, Poulin E, Provencher L, Lamontagne C (1993) Comparison of hydromorphone continuous subcutaneous infusion and basal rate subcutaneous infusion plus PCA in cancer pain: a pilot study. Pain 53(1):27–32PubMedCrossRef

28.

Grochow L, Sheidler V, Grossman S, Green L, Enterline J (1989) Does intravenous methadone provide longer lasting analgesia than intravenous morphine? A randomized, double-blind study. Pain 38(2):151–157PubMedCrossRef

29.

Moulin DE, Johnson NG, Murray-Parsons N, Geoghegan MF, Goodwin VA, Chester MA (1992) Subcutaneous narcotic infusions for cancer pain: treatment outcome and guidelines for use. CMAJ 146(6):891–897PubMedPubMedCentral

30.

Anghelescu DL, Faughnan LG, Oakes LL, Windsor KB, Pei D, Burgoyne LL (2012) Parent-controlled PCA for pain management in pediatric oncology: is it safe? J Pediatr Hematol Oncol 34(6):416–420PubMedPubMedCentralCrossRef

31.

Anghelescu DL, Zhang K, Faughnan LG, Pei D (2015) The safety and effectiveness of patient-controlled analgesia in outpatient children and young adults with cancer: a retrospective study. J Pediatr Hematol Oncol 37(5):378–382PubMedPubMedCentralCrossRef

32.

Goeke H, Herbst M (1993) Patient-controlled analgesia with subcutaneous opoids for out-patients with severe tumour pain. Schmerz 7(1):31–39PubMedCrossRef

33.

Mherekumombe MF, Collins JJ (2015) Patient-controlled analgesia for children at home. J Pain Symptom Manag 49(5):923–927CrossRef

34.

Kanagasundaram SA, Cooper MG, Lane LJ (1997) Nurse-controlled analgesia using a patient-controlled analgesia device: an alternative strategy in the management of severe cancer pain in children. J Paediatr Child Health 33:352–355PubMedCrossRef

35.

Anghelescu DL, Burgoyne LL, Oakes LL, Wallace DA (2005) The safety of patient-controlled analgesia by proxy in pediatric oncology patients. Anesth Analg 101(6):1623–1627PubMedCrossRef

36.

Meuret G, Jocham H (1996) Patient-controlled analgesia (PCA) in the domiciliary care of tumour patients. Cancer Treat Rev 22(Supplement A):137–140PubMedCrossRef

37.

Swanson G, Smith J, Bulik CM (1989) Patient-controlled analgesia for chronic cancer pain in the ambulatory setting: a report of 117 patients. J Clin Oncol 7(12):1903–1908PubMedCrossRef

38.

Kerr IG, Sone M, De Angelis C, Iscoe N, Mackenzie R, Schuellert T (1988) Continuous narcotic infusion with patient-controlled analgesia for chronic cancer pain in outpatients. Ann Intern Med 108(4):554–557PubMedCrossRef

39.

Wagner J, Souders G, Coffman L, Horvath J (1989) Management of chronic cancer pain using a computerized ambulatory patient-controlled analgesia pump. Hosp Pharm 24(8):639–640 642-634PubMed

40.

Lux E, Heine J (2011) Home care treatment of cancer pain patients with patient-controlled analgesia (PCA). Schmerz 25(6):663–667PubMedCrossRef

41.

Schiessl C, Gravou C, Zernikow B, Sittl R, Griessinger N (2008) Use of patient-controlled analgesia for pain control in dying children. Support Care Cancer 16(5):531–536PubMedCrossRef

42.

Fitzgibbon DR, Ready LB (1997) Intravenous high-dose methadone administered by patient controlled analgesia and continuous infusion for the treatment of cancer pain refractory to high-dose morphine. Pain 73(2):259–261PubMedCrossRef

43.

Juba KM, Wahler RG, Daron SM (2013) Morphine and hydromorphone-induced hyperalgesia in a hospice patient. J Palliat Med 16(7):809–812PubMedCrossRef

44.

Goeke H, Herbst M (1995) Patient-controlled analgesia in outpatients with severe cancer pain. Schmerz 9(2):89–92PubMedCrossRef

45.

Gavrin JR, McMenamin EM (2008) Pain management in palliative care oncology patients. Curr Pain Headache Rep 12(4):257–261PubMedCrossRef

46.

Bruera E (1989) The use of subcutaneous patient controlled analgesia. J Pain Symptom Manag 4(2):97–100CrossRef

47.

Dworkin RH, Turk DC, Peirce-Sandner S, Baron R, Bellamy N, Burke LB, Chappell A, Chartier K, Cleeland CS, Costello A (2010) Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain 149:177–193PubMedCrossRef

48.

Turk DC, Dworkin RH, McDermott B, Bellamy N, Burke LB, Chandler J, Cleeland CS, Cowan P, Dimitrova R, Farrar JT, Hertz S, Heyse JF, Iyengar S, Jadad A, Jay GW, Jermano JA, Katz NP, Manning DC, Martin S, Max MB, McGrath P, McQuay H, Quessy S, Rappaport BA, Revicki D, Rothman M, Stauffer JW, Svensson OK, White RE, Witter J (2008) Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations. Pain 139:485–493PubMedCrossRef

49.

Turk DC, Dworkin RH, Burke L, Gershon R, Rothman R, Scott J, Allen RR, Atkinson JH, Chandler J, Cleeland C, Cowan P, Dimitrova R, Dionne R, Farrar JT, Haythornwaite JA, Hertz S, Jadad AR, Jensen MP, Kellstein D, Kerns RD, Manning DC, Martin S, Max MB, McDermott MP, McGrath PA, Moulin DE, Nurmikko T, Quessy S, Raja S, Rappaport BA, Rauschkolb C, Robinson JP, Royal MA, Simon L, Stauffer JW, Stucki G, Tollett J, von Stein T, Wallace MS, Wernicke J, White RE, Williams AC, Witter J, Wyrwich KW (2006) Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations. Pain 125:208–215PubMedCrossRef

50.

Grond S, Zech D, Lehmann KA, Radbruch L, Breitenbach H, Hertel D (1997) Transdermal fentanyl in the long-term treatment of cancer pain: a prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region. Pain 69(1–2):191–198PubMedCrossRef

51.

Kornick CA, Santiago-Palma J, Khojainova N, Primavera LH, Payne R, Manfredi PL (2001) A safe and effective method for converting cancer patients from intravenous to transdermal fentanyl. Cancer 92(12):3056–3061PubMedCrossRef

52.

Kornick CA, Santiago-Palma J, Schulman G, O'Brian PC, Weigand S, Payne R, Manfredi PL (2003) A safe and effective method for converting patients from transdermal to intravenous fentanyl for the treatment of acute cancer-related pain. Cancer 97(12):3121–3124PubMedCrossRef

53.

Santiago-Palma J, Khojainova N, Kornick C, Fischberg DJ, Primavera LH, Payne R, Manfredi P (2001) Intravenous methadone in the management of chronic cancer pain. Cancer 92(7):1919–1925PubMedCrossRef

54.

Radbruch L, Loick G, Schulzeck S, Beyer A, Lynch J, Stemmler M, Lindena G, Lehmann KA (1999) Intravenous titration with morphine for severe cancer pain: report of 28 cases. Clin J Pain 15(3):173–178PubMedCrossRef

55.

Zech DFJ, Grond SUA, Lynch J, Dauer HG, Stollenwerk B, Lehmann KA (1992) Transdermal fentanyl and initial dose-finding with patient-controlled analgesia in cancer pain. A pilot study with 20 terminally ill cancer patients. Pain 50:293–301PubMedCrossRef

56.

Zech DFJ, Lehmann KA (1995) Transdermal fentanyl in combination with initial intravenous dose titration by patient-controlled analgesia. Anti-Cancer Drugs 6(3):44–49PubMedCrossRef

57.

Björkman R, Ullman A, Hedner J, Group MDS (1993) Morphine-sparing effect of diclofenac in cancer pain. Eur J Clin Pharmacol 44(1):1–5PubMedCrossRef

58.

Kalso E, Vainio A, Mattila MJ, Rosenberg PH, Seppälä T (1990) Morphine and oxycodone in the management of cancer pain: plasma levels determined by chemical and radioreceptor assays. Pharmacol Toxicol 67(4):322–328PubMedCrossRef

59.

Bruera E, MacMillan K, Kuehn N, Miller MJ (1992) Circadian distribution of extra doses of narcotic analgesics in patients with cancer pain: a preliminary report. Pain 49(3):311–314PubMedCrossRef

60.

Schiessl C, Sittl R, Griessinger N, Lutter N, Schuettler J (2008) Intravenous morphine consumption in outpatients with cancer during their last week of life-an analysis based on patient-controlled analgesia data. Support Care Cancer 16(8):917–923PubMedCrossRef

61.

Vargas-Schaffer G (2010) Is the WHO analgesic ladder still valid?: twenty-four years of experience. Can Fam Physician 56(6):514–517PubMedPubMedCentral

62.

Franson HE (2010) Postoperative patient-controlled analgesia in the pediatric population: a literature review. AANA J 78(5)

63.

Schmidt P, Otto M, Hechler T, Metzing S, Wolfe J, Zernikow B (2013) Did increased availability of paediatric palliative care lead to improved palliative care outcomes in children with cancer? J Palliat Med 16(9):1034–1039PubMedCrossRef

64.

Wolfe J, Grier HE, Klar N, Levin SB, Ellenbogen JM, Salem-Schatz S, Emanuel EJ, Weeks AC (2000) Symptoms and suffering at the end of life in children with cancer. N Engl J Med 342:326–333PubMedCrossRef

65.

Dupuis LL, Milne-Wren C, Cassidy M, Barrera M, Portwine C, Johnston DL, Silva MP, Sibbald C, Leaker M, Routh S (2010) Symptom assessment in children receiving cancer therapy: the parents perspective. Support Care Cancer 18(3):281–299PubMedCrossRef

66.

Pöder U, Ljungmann G, von Essen L (2010) Parent’s perception of their children’s cancer-related symptoms during treatment: a prospective, longitudinal study. J Pain Symptom Manag 40(5):661–670CrossRef

67.

Kestler SA, LoBiondo-Wood G (2012) Review of symptom experiences in children and adolescents with cancer. Cancer Nurs 35(2):E31–E49PubMedCrossRef

68.

Anghelescu D, Faughnan L, Oakes L, Windsor K, Burgoyne L (2011) F280 the safety of parent (proxy)-controlled analgesia aa a pediatric oncology center. Eur J Pain Supplements 5 (1):147

69.

Etches RC (1994) Respiratory depression associated with patient-controlled analgesia: a review of eight cases. Can J Anaesth 41(2):125–132PubMedCrossRef

70.

Cashman J, Dolin S (2004) Respiratory and haemodynamic effects of acute postoperative pain management: evidence from published data. Br J Anaesth 93(2):212–223PubMedCrossRef

71.

Auvil-Novak SE, Novak RD, Smolensky MH, Kavanagh JJ, Kwan JW, Wharton JT (1988) Twenty-four hour variation in self-administration of morphine sulfate (MS) and hydromorphone (H) by post-surgical gynecologic cancer patients. Annu Rev Chronopharm 5:343–346

72.

Cerchietti LCA, Navigante AH, Körte MW, Cohen AM, Quiroga PN, Villaamil EC, Bonomi MR, Roth BM (2003) Potential utility of the peripheral analgesic properties of morphine in stomatitis-related pain: a pilot study. Pain 105(1):254–273CrossRef

73.

Graves DA, Batenhorst RL, Bennett RL, Wettstein JG, Griffen WO, Wright BD, Foster TS (1983) Morphine requirements using patient-controlled analgesia: influence of diurnal variation and morbid obesity. Clin Pharm 2(1):49–53PubMed

74.

Bruguerolle B, Labrecque G (2007) Rhythmic pattern in pain and their chronotherapy. Adv Drug Deliv Rev 59(9–10):883–895PubMedCrossRef

75.

Labrecque G, Vanier MC (1995) Biological rhythms in pain and in the effects of opioid analgesics. Pharmacol Ther 68(1):129–147PubMedCrossRef

76.

Chassard D, Duflo F, Bouvet L, Boselli E (2007) Chronobiology of postoperative pain: it's time to wake up!/Chronobiologie de la douleur postoperatoire: il est temps de se reveiller ! Can J Anesth 54(9):685–688PubMedCrossRef

77.

Hummel T, Kraetsch HG, Loetsch J, Hepper M, Liefhold J, Kobal G (1995) Analgesic effects of Dihydrocodeine and tramadol when administered either in the morning or evening. Chronobiol Int 12(1):62–72PubMedCrossRef

Titel: Subcutaneous or intravenous opioid administration by patient-controlled analgesia in cancer pain: a systematic literature review
verfasst von: Lisa Nijland
Pia Schmidt
Michael Frosch
Julia Wager
Bettina Hübner-Möhler
Ross Drake
Boris Zernikow
Publikationsdatum: 28.07.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 1/2019
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-018-4368-x

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Subcutaneous or intravenous opioid administration by patient-controlled analgesia in cancer pain: a systematic literature review

Abstract

Context

Objective

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Context

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

The impact of automated screening with Edmonton Symptom Assessment System (ESAS) on health-related quality of life, supportive care needs, and patient satisfaction with care in 268 ambulatory cancer patients

Long-term implications of autologous HCT for caregiver quality of life: how does the survivor’s health matter?

Supportive care needs and associated factors among Chinese cancer survivors: a cross-sectional study

Nutritional status in patients with head and neck cancer undergoing radiotherapy: a longitudinal study

Short and long-term impairments of cardiopulmonary fitness level in previous childhood cancer cases: a systematic review

The role of psychosocial resources for long-term breast, colorectal, and prostate cancer survivors: prevalence and associations with health-related quality of life

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie